Table 8. Results of the sensitivity analysis (per patient).
|
Accelerated phase |
Blast crisis |
|||||
|---|---|---|---|---|---|---|
| Parameter/value | Incremental costs | Incremental QALYs | ICER | Incremental costs | Incremental QALYs | ICER |
| Baselinea | £61 268 | 2.09 | £29 344 | £24 695 | 0.58 | £42 239 |
| Imatinib price per 100 mg | ||||||
| £6.49 (50% discount) | £27 719 | 2.09 | £13 276 | £11 237 | 0.58 | £19 220 |
| £7.79 (40% discount) | £34 439 | 2.09 | £16 495 | £13 929 | 0.58 | £23 824 |
| £9.09 (30% discount) | £41 159 | 2.09 | £19 713 | £16 620 | 0.58 | £28 428 |
| £10.38 (20% discount) | £47 828 | 2.09 | £22 907 | £19 312 | 0.58 | £33 032 |
| £11.68 (10% discount) | £54 548 | 2.09 | £25 126 | £22 004 | 0.58 | £37 636 |
| Rates of response lossb | ||||||
| 13.6% (response achieved from ACCEL) | ||||||
| 30.9% (response achieved from BLAST) | £69 028 | 2.44 | £28 308 | £28 212 | 0.73 | £38 766 |
| 31.5% (response achieved from ACCEL) | ||||||
| 61.3% (response achieved from BLAST) | £54 606 | 1.80 | £30 417 | £22 293 | 0.49 | £45 274 |
| Imatinib utility values | ||||||
| 0.73 (CytR/CHR/PHR) | ||||||
| 0.15 (ACCEL) | ||||||
| 0.02 (BLAST) | £61 268 | 1.43 | £42 958 | £24 695 | 0.29 | £85 981 |
| 1.00 (CytR/CHR/PHR) | ||||||
| 1.00 (ACCEL) | ||||||
| 0.74 (BLAST) | £61 268 | 2.58 | £23 717 | £24 695 | 0.85 | £28 937 |
| Discount rates | ||||||
| 0% (costs), 0% (QALYs) | £69 528 | 2.15 | £32 302 | £26 654 | 0.59 | £44 853 |
| 6% (costs), 0% (QALYs) | £61 268 | 2.15 | £28 465 | £24 695 | 0.58 | £41 556 |
| 6% (costs), 6% (QALYs) | £61 268 | 1.91 | £32 060 | £24 695 | 0.56 | £44 291 |
| 10% (costs), 0% (QALYs) | £56 555 | 2.15 | £26 275 | £23 526 | 0.59 | £39 589 |
| 10% (costs), 10% (QALYs) | £56 555 | 1.77 | £31 907 | £23 526 | 0.54 | £43 932 |
| Extreme scenarios | ||||||
| Worst casec | £61 388 | 1.01 | £60 991 | £23 838 | 0.20 | £122 016 |
| Best cased | £27 959 | 3.06 | £9132 | £11 897 | 1.03 | £11 556 |
Imatinib price per 100 mg=£12.98, monthly probability of response loss (response achieved from ACCEL)=0.0210, monthly probability of response loss (response achieved from BLAST) =0.0664, Imatinib utility (CytR/CHR/PHR)=0.91, Imatinib utility (ACCEL)=0.58, Imatinib utility (BLAST)=0.38, discount rate (costs)=6%, discount rate (QALYs)=1.5%.
At 12 months (responses achieved from ACCEL) and nine months (responses achieved from BLAST).
Imatinib price per 100 mg=£12.98, monthly probability of response loss (response achieved from ACCEL)=0.0310, monthly probability of response loss (response achieved from BLAST)=0.1001, Imatinib utility (CytR/CHR/PHR)=0.73, Imatinib utility (ACCEL)=0.15, Imatinib utility (BLAST)=0.02, discount rate (costs)=0%, discount rate (QALYs)=10%.
Imatinib price per 100 mg=£6.49, monthly probability of response loss (response achieved from ACCEL)=0.0121, monthly probability of response loss (response achieved from BLAST)=0.0402, Imatinib utility (CytR/CHR/PHR)=1.00, Imatinib utility (ACCEL)=1.00, Imatinib utility (BLAST)=0.74, discount rate (costs)=10%, discount rate (QALYs)=0%.